DexCom, Inc. $DXCM Stock Position Decreased by One Way Holdings LLC

One Way Holdings LLC cut its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 5.4% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 269,752 shares of the medical device company’s stock after selling 15,467 shares during the quarter. One Way Holdings LLC owned 0.07% of DexCom worth $23,277,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the company. Latitude Advisors LLC purchased a new stake in shares of DexCom in the 3rd quarter worth about $32,000. Hilton Head Capital Partners LLC raised its position in DexCom by 242.3% during the third quarter. Hilton Head Capital Partners LLC now owns 380 shares of the medical device company’s stock worth $33,000 after acquiring an additional 269 shares during the last quarter. Ascentis Independent Advisors purchased a new stake in shares of DexCom in the first quarter valued at about $25,000. Elevation Wealth Partners LLC lifted its holdings in shares of DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock valued at $35,000 after purchasing an additional 152 shares in the last quarter. Finally, GK Wealth Management LLC acquired a new stake in shares of DexCom in the third quarter valued at approximately $35,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $105.00 price objective (up from $90.00) on shares of DexCom in a research note on Thursday, October 1st. Truist Financial set a $102.00 target price on DexCom and gave the company a “buy” rating in a research note on Friday, September 18th. UBS Group increased their target price on DexCom from $102.00 to $107.00 and gave the company a “buy” rating in a report on Friday. BTIG Research raised their price target on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Finally, Citigroup reissued a “buy” rating and issued a $88.00 price target (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $93.70.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 2,565 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $88.37, for a total value of $226,669.05. Following the completion of the sale, the executive vice president directly owned 126,043 shares in the company, valued at approximately $11,138,419.91. The trade was a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director owned 29,293 shares of the company’s stock, valued at $2,461,783.72. This represents a 18.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 22,822 shares of company stock worth $1,920,193. 0.28% of the stock is owned by company insiders.

DexCom Stock Performance

NASDAQ:DXCM opened at $82.29 on Monday. The firm has a 50 day simple moving average of $85.82 and a 200-day simple moving average of $74.65. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.74 and a quick ratio of 1.40. The firm has a market cap of $30.69 billion, a PE ratio of 32.27, a P/E/G ratio of 1.37 and a beta of 1.45. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.68 by $0.05. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.33 billion. DexCom had a net margin of 19.42% and a return on equity of 37.77%. DexCom’s revenue was up 11.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.61 earnings per share. On average, equities analysts expect that DexCom, Inc. will post 2.67 EPS for the current year.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.